Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company